Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating moderate-to ...

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial ... FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

and immunogenicity of a single dose of the vaccine candidate compared to a placebo in the prevention of IED, which includes sepsis and bacteremia (blood infections). Also Read: Sanofi Genzyme ...